The Opportunity
The heart of insitro’s strategy is the development of novel, cutting edge methods in machine learning and high-throughput biology that address key bottlenecks in the drug development pipeline. To accomplish that, we are putting together a team of life scientists with cutting-edge cellular and technological expertise. In this role, you will lead projects focused on flow-based phenotyping and cell sorting within a high-throughput drug screening platform. You will help define the unmet needs for cross-functional workflows and will establish/execute processes that will enable insitro’s iPSCs platform to operate successfully with regard to cell management and screening. This role provides the opportunity to collaborate with a highly talented multidisciplinary team as you develop cutting-edge activities in a state-of-the-art environment with the aim to accelerate machine learning based drug discoveries. Additional responsibilities include close partnership with our data and process engineering teams to drive the integration of cytometry-based protocols into semi-automated pipelines.
Your primary duties will be to:
You will be joining a biotech startup that has long-term stability due to significant funding, but yet is very much in formation. A lot can change in this early and exciting phase, providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
About You
Benefits at insitro
About insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures.
The company has announced collaborations with Gilead Sciences in the area of NASH (2019) and Bristol Myers Squibb in the area of ALS (2020) and, in mid 2020, completed a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com
Your application was submitted successfully.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.